Evolus Inc. Common Stock (EOLS)

About EOLS

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes vario…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

353

Website

www.evolus.com/

Fundamentals

1-day range

$8.6$8.94

Market cap

$398.42M

P/E (trailing)

—

P/E (forward)

32.17

EPS (trailing)

$-0.67

Dividend yield

—

Beta

1.36

Avg. volume

892.0K

Forecasts

6 analyst ratings

Evolus Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $398.42MP/E —
  $3.86$9.12
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $391.42MP/E 18.65
  $4.3$9.51
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $413.45MP/E —
  $2.72$6.42
• KMDA

  Kamada Ltd. Ordinary Shares

  $8.29

  ▲ 0.36%
  Market cap $417.07MP/E 20.65
  $6.5$9.35
• BNTC

  Benitec Biopharma Inc. Common Stock

  $12.51

  ▼ 1.30%
  Market cap $417.41MP/E —
  $9.85$16.76
• ENTA

  Enanta Pharmaceuticals Inc. Common Stock

  $13.6

  ▼ 1.45%
  Market cap $376.57MP/E —
  $7.05$17.15
• RCKT

  Rocket Pharmaceuticals Inc. Common Stock

  $3.86

  ▲ 6.49%
  Market cap $372.35MP/E —
  $2.53$5.45

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target
  benzinga · 8/25/2026
• HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $13 Price Target
  Benzinga · 8/25/2026
• Following Heightened Competition from Botox, Xeomin, and Long-Acting Daxxify, New Study Evaluates Dysport (abobotulinumtoxinA) Revenue Trajectory Through 2034
  Yahoo · 8/17/2026
• Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
  Yahoo · 8/11/2026
• Evolus: The Injectable Platform Is Becoming The Real Moat
  SeekingAlpha · 8/11/2026
• Evolus, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/6/2026
• Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ...
  Yahoo · 8/6/2026
• Evolus Q2 Earnings Call Highlights
  Yahoo · 8/6/2026
• Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7%
  ChartMill · 8/6/2026

• MOATAZEDI DAVID · March 20, 2026 · Sale

  13.7K @ $4.75
• Avelar Rui · March 20, 2026 · Sale

  3.1K @ $4.75
• MOATAZEDI DAVID · March 17, 2026 · Sale

  116.7K @ $4.89
• Avelar Rui · March 17, 2026 · Sale

  30.0K @ $4.89
• MOATAZEDI DAVID · March 16, 2026 · Option Exercise

  67.5K
• Avelar Rui · March 16, 2026 · Option Exercise

  8.8K

Institutional Ownership

March 31, 2026

Total shares held

45.58M

Total value held

$186.81M

Institutional holders

143